

Title (en)

A DISINTEGRIN AND METALLOPROTEINASE WITH A THROMBOSPONDIN TYPE 1 MOTIF, MEMBER 13 (ADAMTS-13) MUTANTS, COMPOSITIONS AND THERAPEUTIC METHODS THEREOF

Title (de)

DISINTEGRIN UND METALLOPROTEINASE MIT THROMBOSPONDIN TYP 1 MOTIV, MUTANTEN VON ELEMENT 13 (ADAMTS-13), ZUSAMMENSETZUNGEN UND THERAPEUTISCHE VERFAHREN DAFÜR

Title (fr)

DISINTÉGRINE ET MÉTALLOPROTÉINASE AVEC MOTIF DE THROMBOSPONDINE DE TYPE 1, MUTANTS DE L'ÉLÉMENT 13 (ADAMTS -13), COMPOSITIONS ET PROCÉDÉS THÉRAPEUTIQUES ASSOCIÉS

Publication

EP 4196147 A1 20230621 (EN)

Application

EP 21855760 A 20210812

Priority

- US 202063065204 P 20200813
- IL 2021050988 W 20210812

Abstract (en)

[origin: WO2022034595A1] The present invention relates to ADAMTS-13 mutants and/or variant/s that display resistance to tPA cleavage and/or inactivation. The present disclosure further provides fibrinolytic compounds, compositions, combined compositions and kits comprising the ADAMTS-13 mutants disclosed herein, as well as uses thereof for treating coagulation related disorders.

IPC 8 full level

A61K 38/48 (2006.01); **A61P 7/02** (2006.01); **C12N 9/64** (2006.01)

CPC (source: EP IL US)

A61K 38/00 (2013.01 - IL); **A61K 38/1703** (2013.01 - US); **A61K 38/36** (2013.01 - US); **A61K 38/4886** (2013.01 - US);
A61P 7/02 (2018.01 - EP IL US); **C07K 14/46** (2013.01 - US); **C12N 9/6489** (2013.01 - EP IL US); **C12Y 304/24068** (2013.01 - US);
C12Y 304/24087 (2013.01 - EP IL US); **A61K 38/00** (2013.01 - EP); **C07K 2319/35** (2013.01 - US)

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA ME

Designated validation state (EPC)

KH MA MD TN

DOCDB simple family (publication)

WO 2022034595 A1 20220217; EP 4196147 A1 20230621; IL 300596 A 20230401; US 2023295597 A1 20230921

DOCDB simple family (application)

IL 2021050988 W 20210812; EP 21855760 A 20210812; IL 30059623 A 20230213; US 202118041493 A 20210812